For the year ending 2025-12-31, KPHMW had $4,904,758 increase in cash & cash equivalents over the period. -$10,071,965 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| General and administrative | 5,745,087 |
| KIO101 | 17,541 |
| KIO104 | 718,552 |
| KIO201 | 0 |
| KIO301 | 7,217,067 |
| Collaboration credits-Research And Development Tax Credit | 587,447 |
| Unallocated Research And Development | 3,414,684 |
| Research and development | 10,780,397 |
| Collaboration credits-KIO301 | 7,066,237 |
| In-process r&d impairment | 4,624,000 |
| Change in fair value of contingent consideration | -1,252,174 |
| Interest income | 894,002 |
| Other segment expenses | 180,232 |
| Income tax (benefit) expense | -1,282,149 |
| Net (loss) income | -10,835,154 |
| Depreciation and amortization | 24,801 |
| Impairment of intangible assets | 0 |
| Reduction of right-of-use assets | 186,277 |
| Stock-based compensation | 900,236 |
| Impairment of in-process r&d | 4,624,000 |
| Change in fair value of contingent consideration | -1,252,174 |
| Accretion of discount on marketable securities | 112,305 |
| Change in accrued interest on marketable securities | 164,534 |
| Net realized gain on marketable securities | 2,371 |
| Change in unrealized gain on cash equivalents | -119 |
| Deferred taxes | -388,538 |
| Loss on disposal of assets | 0 |
| Prepaid expenses and other current assets | -419,736 |
| Collaboration receivables | 921,573 |
| Tax and other receivables | 1,493,270 |
| Other assets | 34,172 |
| Accounts payable | 1,124,928 |
| Accrued expenses | -2,337,649 |
| Accrued collaboration credit | -1,174,518 |
| Operating lease liabilities | -103,845 |
| Deferred collaboration revenue | 1,250,000 |
| Net cash (used in) provided by operating activities | -9,961,176 |
| Purchases of property and equipment | 110,789 |
| Purchases of marketable securities | 8,175,851 |
| Sales of marketable securities | 305,000 |
| Maturities of marketable securities | 22,408,285 |
| Net cash provided by (used in) investing activities | 14,426,645 |
| Gross proceeds from private placement | 0 |
| Issuance costs for private placement | 0 |
| Exercise of warrants | 265,655 |
| Proceeds from line of credit | 2,750,000 |
| Repayments of line of credit | 2,750,000 |
| Net cash provided by financing activities | 265,655 |
| Effect of exchange rate changes on cash | 173,634 |
| Net increase in cash and cash equivalents | 4,904,758 |
| Cash and cash equivalents, including restricted cash, beginning of year | 3,796,379 |
| Cash and cash equivalents, including restricted cash, end of year | 8,701,137 |
KIORA PHARMACEUTICALS INC (KPHMW)
KIORA PHARMACEUTICALS INC (KPHMW)